These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 10850293)

  • 1. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy.
    Kahn D; Austin JC; Maguire RT; Miller SJ; Gerstbrein J; Williams RD
    Cancer Biother Radiopharm; 1999 Apr; 14(2):99-111. PubMed ID: 10850293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capromab Pendetide imaging of prostate cancer.
    Haseman MK; Rosenthal SA; Polascik TJ
    Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
    Raj GV; Partin AW; Polascik TJ
    Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
    Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy.
    Kahn D; Williams RD; Haseman MK; Reed NL; Miller SJ; Gerstbrein J
    J Clin Oncol; 1998 Jan; 16(1):284-9. PubMed ID: 9440754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
    Koontz BF; Mouraviev V; Johnson JL; Mayes J; Chen SH; Wong TZ; Anscher MS; Sun L; Moul J; Polascik TJ
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):358-61. PubMed ID: 18164863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy.
    Thomas CT; Bradshaw PT; Pollock BH; Montie JE; Taylor JM; Thames HD; McLaughlin PW; DeBiose DA; Hussey DH; Wahl RL
    J Clin Oncol; 2003 May; 21(9):1715-21. PubMed ID: 12721246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman CM; Denardo SJ; O'Donnell RT; Yuan A; Shen S; Goldstein DS; Tuscano JM; Wun T; Chew HK; Lara PN; Kukis DL; Natarajan A; Meares CF; Lamborn KR; DeNardo GL
    Clin Cancer Res; 2005 Aug; 11(16):5920-7. PubMed ID: 16115934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate specific antigen only progression of prostate cancer.
    Moul JW
    J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure.
    Ellis RJ; Zhou EH; Fu P; Kaminsky DA; Sodee DB; Faulhaber PF; Bodner D; Resnick MI
    J Urol; 2008 May; 179(5):1768-73; discussion 1773-4. PubMed ID: 18343445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.
    Kahn D; Williams RD; Manyak MJ; Haseman MK; Seldin DW; Libertino JA; Maguire RT
    J Urol; 1998 Jun; 159(6):2041-6; discussion 2046-7. PubMed ID: 9598514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capromab Pendetide immunoscintigraphy: connecting the dots for prostate cancer imaging.
    Manyak MJ
    Cancer Biother Radiopharm; 2000 Apr; 15(2):127-30. PubMed ID: 10803317
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma.
    Foss FM; Raubitscheck A; Mulshine JL; Fleisher TA; Reynolds JC; Paik CH; Neumann RD; Boland C; Perentesis P; Brown MR; Frincke JM; Lollo CP; Larson SM; Carrasquillo JA
    Clin Cancer Res; 1998 Nov; 4(11):2691-700. PubMed ID: 9829731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy.
    Fang DX; Stock RG; Stone NN; Krynyckyi BR; Kim CK; Machac J
    Tech Urol; 2000 Jun; 6(2):146-50. PubMed ID: 10798816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer.
    Denardo SJ; Richman CM; Goldstein DS; Shen S; Salako Q; Kukis DL; Meares CF; Yuan A; Welborn JL; Denardo GL
    Anticancer Res; 1997; 17(3B):1735-44. PubMed ID: 9179227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
    Tempero M; Leichner P; Baranowska-Kortylewicz J; Harrison K; Augustine S; Schlom J; Anderson J; Wisecarver J; Colcher D
    Clin Cancer Res; 2000 Aug; 6(8):3095-102. PubMed ID: 10955789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.